Ligand Pharmaceuticals Incorporated
LGND
Clasificación en acciones
#3107
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Precio por acción
$291.18
Última sincronización: 2026-07-31
Capitalización bursátil
$5.84B
Cambio (1 día)
-1.73%
Cambio (1 año)
60.30%
País
US
Comercio Ligand Pharmaceuticals Incorporated (LGND)
Categoría
Healthcare
Margen Operativo de Ligand Pharmaceuticals Incorporated (LGND)
Margen Operativo al October 2026 TTM: 34.74%
Según los informes financieros más recientes y el precio de las acciones de Ligand Pharmaceuticals Incorporated, el margen operativo actual (TTM) es 34.74%. Al final de 2023, el margen operativo era 9.09%.
Historial de Margen Operativo de Ligand Pharmaceuticals Incorporated desde 2000 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 34.74% | -356.76% |
| 2024 | -13.53% | -248.84% |
| 2023 | 9.09% | 486.45% |
| 2022 | 1.55% | -95.86% |
| 2021 | 37.47% | 63.41% |
| 2020 | 22.93% | -581.72% |
| 2019 | -4.76% | -107.31% |
| 2018 | 65.11% | 34.94% |
| 2017 | 48.25% | 19.82% |
| 2016 | 40.27% | 5.97% |
| 2015 | 38.00% | 24.96% |
| 2014 | 30.41% | -0.33% |
| 2013 | 30.51% | 1,567.21% |
| 2012 | 1.83% | -178.88% |
| 2011 | -2.32% | -98.14% |
| 2010 | -124.50% | 386.33% |
| 2009 | -25.60% | -92.81% |
| 2008 | -356.13% | -23.69% |
| 2007 | -466.69% | 289.79% |
| 2006 | -119.73% | 698.73% |
| 2005 | -14.99% | -34.43% |
| 2004 | -22.86% | 68.21% |
| 2003 | -13.59% | -45.62% |
| 2002 | -24.99% | -17.55% |
| 2001 | -30.31% | -68.22% |
| 2000 | -95.37% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -98.89% |
US
|
|
| -149.01% | -104.29% |
US
|
|
| 25.57% | -99.26% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.17% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.